Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK2 | P53671 | 3/20 | 0.50 |
| ▸ | AKT1 | P31749 | 3/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.44 |
| ▸ | STK4 | Q13043 | 3/20 | 0.43 |
| ▸ | STK3 | Q13188 | 3/20 | 0.43 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.42 |
| ▸ | MAP3K6 | O95382 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4866858 | 0.99 | LIMK2 (0.49) | LIMK2AKT1F10LRRK2STK4 | |
| SCHEMBL14065312 | 0.95 | LIMK2 (0.48) | LIMK2AKT1F10LRRK2STK4 | |
| SCHEMBL4866804 | 0.90 | LIMK2 (0.62) | LIMK2AKT1LRRK2 | |
| SCHEMBL14065316 | 0.88 | LRRK2 (0.49) | LIMK2AKT1F10LRRK2 | |
| SCHEMBL14065315 | 0.85 | LIMK2 (0.60) | LIMK2AKT1F10LRRK2 | |
| SCHEMBL14065320 | 0.84 | AKT2 (0.53) | F10 | |
| SCHEMBL14065313 | 0.83 | LIMK2 (0.72) | LIMK2F10 | |
| SCHEMBL14073937 | 0.79 | F10 (0.47) | LIMK2F10 | |
| SCHEMBL4290392 | 0.77 | LIMK2 (0.62) | LIMK2AKT1 | |
| SCHEMBL4727626 | 0.75 | AKT1 (0.56) | LIMK2AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423043-B2 | 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds | LEXICON PHARMACEUTICALS, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423043-B2 | 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds | LEXICON PHARMACEUTICALS, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423043-B2 | 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds | LEXICON PHARMACEUTICALS, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-20060189638-A1 | kinase inhibitor; proliferative diseases such as cancer, cancer metastasis, inflammation, arthritis, and diseases characterized by abnormal or inappropriate angiogenesis | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189638-A1 | kinase inhibitor; proliferative diseases such as cancer, cancer metastasis, inflammation, arthritis, and diseases characterized by abnormal or inappropriate angiogenesis | CDK4, CDK2, MKI67 | LIMK2 457/4885AKT1 237/4885F10 3652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.